February 8, 2018 2:30 pm JST

Fujifilm to partner with Takeda on regenerative heart medicine

Clinical trials scheduled for drug that uses induced pluripotent stem cells

NIKKEI Staff writers

TOKYO -- Fujifilm will partner with Takeda Pharmaceutical to develop and sell a regenerative medicine product for heart patients, the company announced Thursday.

The deal combines Fujifilm's manufacturing expertise with Takeda's experience in clinical tests and pharmaceutical sales. The product, which is being developed by Fujifilm's U.S. subsidiary Cellular Dynamics International, uses induced pluripotent stem cells.

The companies expect the product, which helps restore the heart muscle in patients with grave heart failure symptoms, to begin clinical tests as early as 2019. It is currently being tested on lab animals.

The deal represents the first tie-up for the two companies.

Fujifilm acquired Wako Pure Chemical Industries, a laboratory chemicals manufacturer, from Takeda in 2017.

Takeda Pharmaceutical Co., Ltd.

Japan

Market(Ticker): TKS(4502)
Sector:
Industry:
Health Technology
Pharmaceuticals: Major
Market cap(USD): 44,072.9M
Shares: 791.07M

Get Insights on Asia In Your Inbox

To read the full story, Subscribe or Log in

Get your first month for $0.99

Redeemable only through the Subscribe button below

Once subscribed, you can…

  • Read all stories with unlimited access
  • Use our smartphone and tablet apps

To read the full story, Subscribe or Log in

3 months for $9
SUBSCRIBE TODAY

Take advantage of this limited offer.
Subscribe now to get unlimited access to all articles.

To read the full story, Update your account

Resubscribe now to continue reading.
BEST OFFER:
Only US$ 9.99 per month for a full-year subscription

To read the full story, Subscribe or Log in

Once subscribed, you can…

  • Read all stories with unlimited access
  • Use our smartphone and tablet apps

To read the full story, Subscribe or Log in

3 months for $9
SUBSCRIBE TODAY

Take advantage of this limited offer.
Subscribe now to get unlimited access to all articles.

To read the full story, Update your account

We could not renew your subscription.
You need to update your payment information.